Karo Pharma AB (publ) (OM:KARO) entered into an agreement to acquire E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT) for an implied enterprise value of £200 million on December 24, 2021. The Proposed Sale, if completed, would be another step forward in Reckitt's plan to actively manage its portfolio for higher growth, following the recent divestments of its IFCN business in China and its Scholl brand, as well as the acquisition of Biofreeze. The transaction is expected to close in the second quarter of 2022. As of April 1, 2022. All conditions to the completion of the transaction have been satisfied. Matthew Appleton, Gareth Irving, Lydia Challen and Alasdair Balfour of Allen & Overy LLP acted as legal advisor to Reckitt Benckiser Group plc. Centerview Partners UK LLP acted as financial advisor to Reckitt Benckiser Group plc .

Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT) on April 1, 2022.